Changing Lives: Novartis’ LUTATHERA in Pediatric Oncology

adicionou um novo artigo Outro

2025-09-16 10:50:04 -

Novartis’ LUTATHERA (lutetium Lu 177 dotatate) has already marked a turning point in the treatment of gastroenteropancreatic neuroendocrine tumors (GEP-NETs). The recent extension of approval to pediatric patients expands its reach and reinforces Novartis’ leadership in oncology. While the lutathera cost remains a key discussion, this milestone highlights the therapy’s value...

0 Comentários 0 Compartilhamentos 461 Visualizações 0 Anterior